Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 24916185)

1.

Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.

Jegaskanda S, Vandenberg K, Laurie KL, Loh L, Kramski M, Winnall WR, Kedzierska K, Rockman S, Kent SJ.

J Infect Dis. 2014 Dec 1;210(11):1811-22. doi: 10.1093/infdis/jiu334. Epub 2014 Jun 10.

PMID:
24916185
2.

Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1.

Jegaskanda S, Laurie KL, Amarasena TH, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks AG, Reading PC, Kent SJ.

J Infect Dis. 2013 Oct 1;208(7):1051-61. doi: 10.1093/infdis/jit294. Epub 2013 Jun 28.

3.

Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques.

Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ.

J Virol. 2013 May;87(10):5512-22. doi: 10.1128/JVI.03030-12. Epub 2013 Mar 6.

4.

Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.

Srivastava V, Yang Z, Hung IF, Xu J, Zheng B, Zhang MY.

J Virol. 2013 May;87(10):5831-40. doi: 10.1128/JVI.00273-13. Epub 2013 Mar 13.

5.

IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States.

Li ZN, Lin SC, Carney PJ, Li J, Liu F, Lu X, Liu M, Stevens J, Levine M, Katz JM, Hancock K.

Clin Vaccine Immunol. 2014 Aug;21(8):1054-60. doi: 10.1128/CVI.00129-14. Epub 2014 May 28.

6.

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice.

Hohenadl C, Wodal W, Kerschbaum A, Fritz R, Howard MK, Farcet MR, Portsmouth D, McVey JK, Baker DA, Ehrlich HJ, Barrett PN, Kreil TR.

Virol J. 2014 Apr 16;11:70. doi: 10.1186/1743-422X-11-70.

7.

Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, Kent SJ.

J Immunol. 2013 Feb 15;190(4):1837-48. doi: 10.4049/jimmunol.1201574. Epub 2013 Jan 14.

8.

Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.

Liu X, Liu Y, Zhang Y, Chen Z, Tang Z, Xu Q, Wang Y, Zhao P, Qi Z.

PLoS One. 2013;8(3):e58810. doi: 10.1371/journal.pone.0058810. Epub 2013 Mar 19.

9.

Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.

Co MD, Terajima M, Thomas SJ, Jarman RG, Rungrojcharoenkit K, Fernandez S, Yoon IK, Buddhari D, Cruz J, Ennis FA.

Viral Immunol. 2014 Oct;27(8):375-82. doi: 10.1089/vim.2014.0061. Epub 2014 Aug 20.

PMID:
25141276
10.

Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.

Jegaskanda S, Amarasena TH, Laurie KL, Tan HX, Butler J, Parsons MS, Alcantara S, Petravic J, Davenport MP, Hurt AC, Reading PC, Kent SJ.

J Virol. 2013 Dec;87(24):13706-18. doi: 10.1128/JVI.01666-13. Epub 2013 Oct 9.

11.

Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations.

Hong DK, Tremoulet AH, Burns JC, Lewis DB.

Pediatr Infect Dis J. 2011 Jan;30(1):67-9. doi: 10.1097/INF.0b013e3181f127be.

12.

1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.

Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P.

J Infect Dis. 2013 Jan 1;207(1):98-105. doi: 10.1093/infdis/jis652. Epub 2012 Oct 18.

13.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, GarcĂ­a-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

14.

Seasonal influenza vaccination is the strongest correlate of cross-reactive antibody responses in migratory bird handlers.

Oshansky CM, Wong SS, Jeevan T, Smallwood HS, Webby RJ, Shafir SC, Thomas PG.

MBio. 2014 Dec 9;5(6):e02107. doi: 10.1128/mBio.02107-14.

15.

Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian 'avian-like' H1N1 swine viruses in mice.

Castrucci MR, Facchini M, Di Mario G, Garulli B, Sciaraffia E, Meola M, Fabiani C, De Marco MA, Cordioli P, Siccardi A, Kawaoka Y, Donatelli I.

Influenza Other Respir Viruses. 2014 May;8(3):367-75. doi: 10.1111/irv.12221. Epub 2013 Dec 23.

16.

Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties.

Strengell M, Ikonen N, Ziegler T, Julkunen I.

PLoS One. 2011;6(10):e25848. doi: 10.1371/journal.pone.0025848. Epub 2011 Oct 11.

17.

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J.

PLoS One. 2008;3(12):e3942. doi: 10.1371/journal.pone.0003942. Epub 2008 Dec 16.

18.

Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009.

Hardelid P, Andrews NJ, Hoschler K, Stanford E, Baguelin M, Waight PA, Zambon M, Miller E.

Health Technol Assess. 2010 Dec;14(55):115-92. doi: 10.3310/hta14550-03.

19.

Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine.

He XS, Sasaki S, Baer J, Khurana S, Golding H, Treanor JJ, Topham DJ, Sangster MY, Jin H, Dekker CL, Subbarao K, Greenberg HB.

J Infect Dis. 2013 Jan 15;207(2):288-96. doi: 10.1093/infdis/jis664. Epub 2012 Oct 29.

20.

An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Krammer F, Jul-Larsen A, Margine I, Hirsh A, Sjursen H, Zambon M, Cox RJ.

Clin Vaccine Immunol. 2014 Aug;21(8):1153-63. doi: 10.1128/CVI.00272-14. Epub 2014 Jun 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk